Capstone Investment Advisors LLC Purchases New Shares in BeiGene, Ltd. (NASDAQ:BGNE)

Capstone Investment Advisors LLC acquired a new position in shares of BeiGene, Ltd. (NASDAQ:BGNE - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 5,311 shares of the company's stock, valued at approximately $1,192,000.

A number of other large investors have also recently bought and sold shares of BGNE. Swedbank AB bought a new stake in shares of BeiGene during the 1st quarter worth $2,596,000. Raymond James & Associates grew its holdings in shares of BeiGene by 0.4% during the 2nd quarter. Raymond James & Associates now owns 21,275 shares of the company's stock valued at $3,035,000 after purchasing an additional 76 shares during the last quarter. EFG Asset Management North America Corp. increased its position in BeiGene by 21.7% during the 2nd quarter. EFG Asset Management North America Corp. now owns 17,780 shares of the company's stock worth $2,540,000 after purchasing an additional 3,170 shares in the last quarter. Van ECK Associates Corp lifted its stake in BeiGene by 8.9% in the 2nd quarter. Van ECK Associates Corp now owns 95,577 shares of the company's stock valued at $13,636,000 after purchasing an additional 7,816 shares during the last quarter. Finally, Fiera Capital Corp lifted its stake in BeiGene by 45.9% in the 2nd quarter. Fiera Capital Corp now owns 3,736 shares of the company's stock valued at $533,000 after purchasing an additional 1,176 shares during the last quarter. 48.55% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on BGNE. TD Cowen upped their price target on shares of BeiGene from $254.00 to $260.00 and gave the stock a "buy" rating in a report on Wednesday, November 13th. Citigroup upped their target price on BeiGene from $269.00 to $288.00 and gave the stock a "buy" rating in a report on Thursday, August 8th. JMP Securities started coverage on BeiGene in a research note on Wednesday, September 18th. They set a "market outperform" rating and a $288.00 price target on the stock. StockNews.com downgraded shares of BeiGene from a "buy" rating to a "hold" rating in a research report on Thursday, November 21st. Finally, JPMorgan Chase & Co. upped their price target on shares of BeiGene from $200.00 to $235.00 and gave the company an "overweight" rating in a research report on Tuesday, October 22nd. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $247.07.

BeiGene Trading Up 4.3 %

Shares of BGNE stock traded up $8.84 during mid-day trading on Friday, hitting $215.00. The company's stock had a trading volume of 258,573 shares, compared to its average volume of 266,091. BeiGene, Ltd. has a 52 week low of $126.97 and a 52 week high of $248.16. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.72 and a current ratio of 1.93. The company's fifty day simple moving average is $212.16 and its 200-day simple moving average is $184.09. The company has a market cap of $20.94 billion, a PE ratio of -25.02 and a beta of 0.63.

BeiGene (NASDAQ:BGNE - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.11) by ($0.04). The business had revenue of $1 billion for the quarter, compared to the consensus estimate of $983.26 million. BeiGene had a negative return on equity of 25.12% and a negative net margin of 25.94%. BeiGene's quarterly revenue was up 28.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.01 earnings per share. As a group, equities research analysts expect that BeiGene, Ltd. will post -5.38 earnings per share for the current fiscal year.

Insider Buying and Selling at BeiGene

In other BeiGene news, CEO John Oyler sold 6,175 shares of the company's stock in a transaction on Tuesday, October 8th. The shares were sold at an average price of $232.22, for a total transaction of $1,433,958.50. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, COO Xiaobin Wu sold 5,556 shares of BeiGene stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $189.65, for a total transaction of $1,053,695.40. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 23,070 shares of company stock valued at $4,901,050. Corporate insiders own 7.43% of the company's stock.

About BeiGene

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.